^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    ERBB3 mutation

    i
    Other names: ERBB3, HER3, LCCS2, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3
    Entrez ID:
    2065
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    1year
    Brilliant talk this morning from #NSCLC #EGFR expert @RamalingamMD who is one of our favorites! Acquired resistance #MET; #C797S etc.; novel therapies including mutation-agnostic #patritumab deruxtecan, the #HER3-DXd #ADC; plasma/tissue tips re #SCLC and #LUSC conversion—a tour… https://t.co/y0O8xAxQGj (@Exon20Group)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR C797S • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    1year
    Mechanisms of resistance to ALK TKIs are: ALK alterations (mutation and amplification), bypass signal pathways (EGFR/HER3, KIT proto-oncogene receptor tyrosine kinase, KRAS, ILGF-R, M-E-T-HGF, MAPK, and others (E-M-T, P-gp, TP53, transformation to SCLC) https://t.co/oXjoSjwflx (@MLPOncoData)
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    ALK mutation • ERBB3 mutation
    1year
    Presidential session @JSMO_official. Prof. Hidetoshi Hayashi presented the U31402-A-U102 Study of HER3‑DXd in EGFR-Mutated NSCLC. FREE on-demand access for international audiences! https://t.co/M3njqk44vJ #JSMO2023 #LCSM (@HHorinouchi)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    over1year
    Delighted to share my paper co-authored with esteemed colleagues from @ULHospitals @TheCarolineFDN &🇧🇭.The paper reviews current progress & emerging clinical data related to use of anti-HER3 in trt of #EGFR-mutant NSCLC & HER3-MBC https://t.co/1wARLIHSFu. @MedComm_MC @WileyHeal (@YasarHammor)
    Clinical data
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • ERBB3 mutation
    over1year
    Antibody drug conjugates increasingly relevant for NSCLC as discussed by Dr. @benlevylungdoc at #DCLung22 with highlights including trastuzumab deruxtecan (T-DXd) in #HER2 mutant NSCLC (dose is 5.4 mg/kg) and patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC. #LCSM (@StephenVLiu)
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • patritumab deruxtecan (U3-1402)
    over1year
    https://t.co/id1APCulbd Patritumab deruxtecan also with activity in non-EGFR mutated NSCLC. I suspect a lot of bystander effect with these ADCs (including those targeting TROP2). Mutation presence or level of expression (HER3 or TROP2) seems to be less important…so far. (@ryangentzler)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 expression • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    2years
    #TTLC22 Dr. Pasi Janne outlines HER2/HER3 ADCs - lots of excitement here. TDXd in #HER2 NSCLC (mutant > IHC positive). Patritumab deruxtecan (HER3 DXd) with exciting data in #EGFR mutant NSCLC. Importantly, patritumab efficacy seen across various mechanisms of TKI resistance. (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    over2years
    Nice work showing potential MOA of HER3-targeted therapy in EGFR-mutated NSCLC with acquired resistance. (@drgandara)
    Preclinical
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    over2years
    Phase I study of patritumab deruxtecan (HER3-DXd) in #EGFR mutant NSCLC post-TKI now @CD_AACR. HER3-DXd is an antibody-drug conjugate targeting HER3. Here, RR 39%, mPFS 8.2m with efficacy across different mechanisms of TKI resistance. @OncoAlert #LCSM https://t.co/aMLgaEBJN4 (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    over2years
    The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer @eugeneahn @CancerCenter @ASCO #ASCO21 #gyncsm https://t.co/9n2OmzcUwy (@OncLive)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression • ERBB3 expression • ERBB3 mutation
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost3years
    FAT1 mutation associated with increased HER3 signaling may provide a target for this common alteration in HPV-negative head and neck cancer. https://t.co/SM3Clkg66C (@DrEzraCohen)
    ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3) • FAT1 (FAT atypical cadherin 1)
    |
    ERBB3 mutation • FAT1 mutation
    almost3years
    The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer. @eugeneahn @CancerCenter @ASCO #ASCO21 #gyncsm https://t.co/ObnExyFHoZ (@OncLive)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 amplification • HER-2 mutation • HER-2 expression • ERBB3 expression • ERBB3 mutation
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost3years
    #asco21 5508: #TAPUR study of pertuzumab + trastuzumab in uterine cancer w/ ERBB2 amplification, overexpression, or mutation (+ one with ERBB3 amplification). Evidence of anti-tumor activity in heavily pre-treated pts. (@jrgralow)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 overexpression • HER-2 amplification • HER-2 mutation • ERBB3 mutation • ERBB3 amplification
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost3years
    #ASCO21 HER3-Dxd in EGFR TKI-resistant EGF mutant #LCSM (@GlopesMd)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    almost3years
    #ASCO21 Presentation of escalation/expansion cohorts patritumab deruxtecan (anti-HER3 ADC) in #EGFR mutant NSCLC post-TKI. #LCSM @OncoAlert (@StephenVLiu)
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    almost3years
    Will be presenting on behalf of the TAPUR study group - Pertuzumab plus trastuzumab for uterine cancer (UC) with ERBB2 or ERBB3 amplification, overexpression or mutation. See you virtually #ASCO21 on 6/7 Mon 9:45am ET! @ASCO @CancerCenter @Integrativeonc (@eugeneahn)
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 overexpression • HER-2 amplification • ERBB3 mutation • ERBB3 amplification
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    3years
    #WCLC20 Excited about this one: phase I results of the HER3 ADC patritumab deruxtecan (HER3-DXd; U3-1402) in #EGFR mutant #NSCLC presented by @HelenaYu923 #LCSM @IASLC @OncoAlert (@StephenVLiu)
    P1 data
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    3years
    #WCLC20 This poster outlines biomarker work in the phase I study of patritumab deruxtecan (HER3-DXd), a HER3-ADC, focused on patients with #EGFR mutant NSCLC after prior TKI and chemotherapy. Note diversity of EGFR TKI resistance mechanisms in this small sample! #LCSM @OncoAlert (@StephenVLiu)
    Clinical • P1 data
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402)
    3years
    #WCLC20 The efficacy of HER3-DXd in #EGFR mutant NSCLC was seen across various resistance mechanisms and for such a heterogeneous pretreated population, very promising activity. #LCSM (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    over3years
    #ESMO20 Dr. @HelenaYu923 presents data on patritumab deruxtecan (U3-1402), a HER3-ADC for patients with #EGFR mutant NSCLC. #LCSM @OncoAlert (@StephenVLiu)
    Clinical
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • ERBB3 mutation
    |
    patritumab deruxtecan (U3-1402) • patritumab (U3-1287)
    over3years
    #ESMO20 HER3 is expressed in 80% of #EGFR mutant NSCLC hence this ADC approach. Patritumab is an ADC with HER3 Ab linked to a topoisomerase I payload. Here, data from escalation (n=12) and expansion (n=45) in EGFR+ NSCLC after TKI (expansion was post chemo as well). #LCSM (@StephenVLiu)
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    EGFR mutation • EGFR expression • ERBB3 expression • ERBB3 mutation
    |
    patritumab (U3-1287)